Abstract
Many microRNAs reside in clusters in the genome, are generally similar in sequence, are transcribed in the same direction, and usually function synergistically. The miR-183/96/182 cluster is composed of 3 miRNA genes, and increased expression of miR-183, 96 and 182 are implicated in glioma carcinogenesis. Knockdown of individual components or of the entire miR-183/96/182 cluster inhibits the survival of glioma cells by regulating the ROS-induced apoptosis pathway. Furthermore, inhibition of the miR-183/96/182 cluster induced ROS-mediated AKT/survival independent of three target genes FGF9, CPEB1, and FOXO1, and inhibition of the miRNA cluster induced p53/apoptosis signaling, which was dependent on these same genes. In addition, knockdown of the miR-183/96/182 cluster enhanced the anticancer effect of Temozolomide on glioma cells by the ROS-mediated apoptosis pathway. Therefore, the miR- 183/96/182 cluster may be a pleiotropic target for glioma therapy.
Keywords: AKT, apoptosis, glioma, micoRNA, miR-96, miR-182, miR-183, mitochondrial membrane potential, P53, temozolomide.
Current Cancer Drug Targets
Title:The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Volume: 13 Issue: 2
Author(s): Hailin Tang, Yanhui Bian, Chaofeng Tu, Zeyou Wang, Zhibin Yu, Qing Liu, Gang Xu, Minghua Wu and Guiyuan Li
Affiliation:
Keywords: AKT, apoptosis, glioma, micoRNA, miR-96, miR-182, miR-183, mitochondrial membrane potential, P53, temozolomide.
Abstract: Many microRNAs reside in clusters in the genome, are generally similar in sequence, are transcribed in the same direction, and usually function synergistically. The miR-183/96/182 cluster is composed of 3 miRNA genes, and increased expression of miR-183, 96 and 182 are implicated in glioma carcinogenesis. Knockdown of individual components or of the entire miR-183/96/182 cluster inhibits the survival of glioma cells by regulating the ROS-induced apoptosis pathway. Furthermore, inhibition of the miR-183/96/182 cluster induced ROS-mediated AKT/survival independent of three target genes FGF9, CPEB1, and FOXO1, and inhibition of the miRNA cluster induced p53/apoptosis signaling, which was dependent on these same genes. In addition, knockdown of the miR-183/96/182 cluster enhanced the anticancer effect of Temozolomide on glioma cells by the ROS-mediated apoptosis pathway. Therefore, the miR- 183/96/182 cluster may be a pleiotropic target for glioma therapy.
Export Options
About this article
Cite this article as:
Tang Hailin, Bian Yanhui, Tu Chaofeng, Wang Zeyou, Yu Zhibin, Liu Qing, Xu Gang, Wu Minghua and Li Guiyuan, The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas, Current Cancer Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1568009611313020010
DOI https://dx.doi.org/10.2174/1568009611313020010 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Medical Imaging Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Extracorporeal Shock Wave Therapy in Inflammatory Diseases: Molecular Mechanism that Triggers Anti-Inflammatory Action
Current Medicinal Chemistry Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Modern Treatments for Gliomas Improve Outcome
Current Cancer Therapy Reviews HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis
Current Pharmaceutical Design A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets